B.C. Cho

LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

B.C. Cho, Enriqueta Felip, Alexander I. Spira et al. · Annals of Oncology · 2023 · 83 citations · Full text

Lba14 Amivantamab, Medicine, Phase Iii +7

1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Luis Paz‐Ares, M-J. Ahn, Aaron Lisberg et al. · Annals of Oncology · 2023 · 48 citations

Actionable Genomic Alterations, Medicine, Tumor Immunity +6

1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

Helena A. Yu, Helen Ambrose, Christina S. Baik et al. · Annals of Oncology · 2021 · 46 citations

Prognostic Biomarkers, Medicine, Pathology +6

OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

Myung‐Ju Ahn, Ji‐Youn Han, Lecia V. Sequist et al. · Journal of Thoracic Oncology · 2017 · 35 citations · Full text

Oncology, Medicine, Pharmacology +8

MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors

B.C. Cho, Robert C. Doebele, Misako Nagasaka et al. · Journal of Thoracic Oncology · 2021 · 34 citations · Full text

Trident-1 Study, Tumoral Pathology, Ma11.07 Phase 1/2 +8